Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF 56 Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus rates TSXV:WOLF with a GF Score™ of 56/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 290 Drug Manufacturers companies, Grey Wolf Health ranks worse than 344827.24% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Grey Wolf Health's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WOLF vs ROL, SCI, FTDR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Grey Wolf Health and its competitors. According to the industry distribution chart, Grey Wolf Health ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Grey Wolf Health's Buyback Yield % too high?
Grey Wolf Health's current Buyback Yield % is 0.00. Based on the distribution chart, Grey Wolf Health ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grey Wolf Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's Buyback Yield % compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #999999 out of 290 companies for Buyback Yield %. This places Grey Wolf Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Grey Wolf Health and its competitors. Grey Wolf Health's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.60 — trading 45.5% above its estimated fair value. The current Buyback Yield % is 0.00. Grey Wolf Health's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.60 is trading 45.5% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
Buyback Yield %: 0.00
GF Value™: C$1.10 vs. price of C$1.60 (45.5% above fair value)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
56GF Score
Get the complete analysis for TSXV:WOLF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
